Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||BRAF mutant|
|Indication/Tumor Type||thyroid gland cancer|
|Response Type||predicted - sensitive|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|BRAF mutant||thyroid gland cancer||predicted - sensitive||Selumetinib||Phase I||Actionable||In a Phase I study, Koselugo (selumetinib) demonstrated an increase in iodine uptake and retention in a subgroup of patients with thyroid cancer that was refractory to radioiodine, including patients with BRAF and NRAS mutations (PMID: 23406027).||23406027|
|PubMed Id||Reference Title||Details|
|(23406027)||Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.||Full reference...|